Hun Ju Lee, MD | Authors

January 23, 2023

Hun Ju Lee, MD, reviews results from part C of the phase 2 SGN35-27 trial for patients with early-stage classical Hodgkin lymphoma treated with brentuximab vedotin plus nivolumab, doxorubicin, and dacarbazine.

January 20, 2023

An expert from The University of Texas, MD Anderson Cancer Center says that a brentuximab vedotin–based combination was well-tolerated in patients with advanced-stage Hodgkin lymphoma, according to results presented at 2022 ASH.

December 18, 2022

In a conversation during the 2022 American Society of Hematology Annual Meeting, an expert from the University of Texas MD Anderson Cancer Center, spoke to how treatments have improved for patients with mantle cell lymphoma.